Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - satralizumab - solucion inyectable - 120mg/1ml - por jeringa precargada 1.00 u - - satralizumab

Unión Europea - español - EMA (European Medicines Agency)

eli lilly and company (ireland) limited - ixekizumab - psoriasis - inmunosupresores - la placa psoriasistaltz está indicado para el tratamiento de moderada a severa psoriasis en placas en los adultos que son candidatos para la terapia sistémica. psoriásica arthritistaltz, solo o en combinación con metotrexato, está indicado para el tratamiento de la artritis psoriásica activa en pacientes adultos que han respondido adecuadamente o que son intolerantes a uno o más modificadores de la enfermedad reumática de drogas (dmard) terapias.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - inmunosupresores - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Unión Europea - español - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriasis - inmunosupresores, inhibidores de la interleucina, - ilumetri está indicado para el tratamiento de adultos con moderada a severa psoriasis en placas que son candidatos para la terapia sistémica.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - inmunosupresores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Unión Europea - español - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - inmunosupresores - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colitis, ulcerativo - inmunosupresores - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Unión Europea - español - EMA (European Medicines Agency)

recordati netherlands b.v. - siltuximab - hiperplasia del ganglio linfático gigante - inmunosupresores - sylvant está indicado para el tratamiento de pacientes adultos con enfermedad de castleman multicéntrica (mcd que son virus de inmunodeficiencia humana (vih) negativo y humano herpesvirus-8 (humano hhv-8) negativo.

Unión Europea - español - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - inmunosupresores - kyntheum está indicado para el tratamiento de la psoriasis en placas de moderada a grave en pacientes adultos candidatos a terapia sistémica.

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - inmunosupresores - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.